Abstract
There are currently five compounds (clobazam, felbamate, lamotrigine, topiramate, rufinamide) available for prescription with a demonstrated efficacy on drop seizures for Lennox-Gastaut syndrome (LGS). There are also currently new and under-investigation compounds. This paper gives an overview on these novel developments for LGS based on the lecture given at the French Chapter meeting of the International League Against Epilepsy (ILAE) held in Paris in October 2019. Five compounds were discussed. Epidiolex (cannabidiol) has been approved recently based on positive randomized control trials in LGS patients. Four drugs are under investigation according to a search on the ‘clinicaltrials.gov’ database. Perampanel and fenfluramine are both being studied in ongoing phase 3 studies. Two compounds are in an earlier stage of development with ongoing phase 1 and 2 studies: carisbamate and OV953. We summarized the publicly available data. Based on these drug development programs, we can expect that new compounds will become available for LGS in the next years, possibly resulting in new treatment paradigms.
Keywords: Cannabidiol, Carisbamate, Fenfluramine, Lennox-Gastaut syndrome, Perampanel
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome.Acta Neurol Scand. 2013 Aug;128(2):91-9. doi: 10.1111/ane.12086. Epub 2013 Feb 15.PMID: 23410109 Review.
-
The pharmacological management of Lennox-Gastaut syndrome and critical literature review.Seizure. 2018 Dec;63:17-25. doi: 10.1016/j.seizure.2018.10.016. Epub 2018 Oct 26.PMID: 30391662 Review.
-
Treatment of Lennox-Gastaut syndrome.Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD003277. doi: 10.1002/14651858.CD003277.pub3.PMID: 23450537 Free PMC article. Review.
-
Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.Ann Pharmacother. 2019 Jun;53(6):603-611. doi: 10.1177/1060028018822124. Epub 2019 Jan 8.PMID: 30616356 Review.
-
Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.Pharmacoeconomics. 2012 Mar;30(3):247-56. doi: 10.2165/11208630-000000000-00000.PMID: 22332960 Review.
Publication types
LinkOut – more resources
-
Full Text Sources